DDInter1666 DDInter625
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain.
Sildenafil {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Elagolix
Sildenafil {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Sildenafil {u} (Compound) binds {v} (Gene) ABCC5
ABCC5 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Elagolix
Sildenafil {u} (Compound) causes {v} (Side Effect) Bone disorder
Bone disorder {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Elagolix
Sildenafil {u} (Compound) binds {v} (Gene) ABCC5
ABCC5 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Sildenafil {u} (Compound) causes {v} (Side Effect) Bone disorder
Bone disorder {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Sildenafil {u} (Compound) binds {v} (Gene) ABCC5
ABCC5 {u} (Gene) is bound by {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Sildenafil {u} (Compound) binds {v} (Gene) ABCC5
ABCC5 {u} (Gene) is upregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Sildenafil {u} (Compound) causes {v} (Side Effect) Hernia
Hernia {u} (Side Effect) is caused by {v} (Compound) Nefazodone
Nefazodone {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Sildenafil (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Sildenafil (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Sildenafil (Compound) binds ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Sildenafil (Compound) causes Bone disorder (Side Effect) and Bone disorder (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Sildenafil (Compound) binds ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Sildenafil (Compound) causes Bone disorder (Side Effect) and Bone disorder (Side Effect) is caused by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Sildenafil (Compound) binds ABCC5 (Gene) and ABCC5 (Gene) is bound by Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Elagolix
Sildenafil (Compound) binds ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Elagolix
Sildenafil (Compound) causes Hernia (Side Effect) and Hernia (Side Effect) is caused by Nefazodone (Compound) and Nefazodone may lead to a major life threatening interaction when taken with Elagolix
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix